Separating AI hype from reality.

Isomorphic Labs Raises $5 Billion Series C to Push AI-Designed Drugs Toward Clinical Trials

November 17, 2026 · Isomorphic Labs · Funding

Isomorphic Labs, the AI drug discovery company spun out of Google DeepMind in 2021, announced a $5 billion Series C financing round on Nov. 17. The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor. All existing backers — including Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund — also participated. The company did not disclose its valuation; Bloomberg reported on 4 November that talks valued it at about $50 billion [2].

The financing brings Isomorphic's total external funding to roughly $7.7 billion: $600 million in its first outside round in March 2025, $2.1 billion in a Series B in May 2026, and now the Series C [2]. Each round has been larger than the last [2].

What the money is for

Isomorphic says the proceeds will scale its proprietary drug design engine, IsoDDE, expand its foundational biology models, and build "AI-first translational and clinical development infrastructure" to advance candidates into human trials [1]. The company also plans to deepen a partner ecosystem for mechanistic disease biology and build global "AI-led bioengineering" capacity [1].

IsoDDE is described as a suite of foundational simulation models that work across multiple therapeutic areas and drug modalities, paired with proprietary agents that "navigate and reason over highly complex biological systems" [1]. The company claims these models push predictions "towards experimental accuracy" and have yielded "positive preclinical results" in internal oncology and immunology programs and partnered work, "setting the stage for clinical entry" [1].

Claims versus disclosed evidence

The announcement uses language typical of the sector: molecules designed with "unprecedented precision and speed," "repeatable scientific advancements" every week, and teams "routinely solving complex biological problems that have stalled traditional research for decades" [1].

Isomorphic's partnered programs provide external validation of a sort. Deals with Eli Lilly and Novartis, announced in 2024, carry potential milestone payments of nearly $3 billion combined; Johnson & Johnson is also a partner [2].

DeepMind lineage and the AlphaFold factor

Isomorphic was founded by Sir Demis Hassabis, who led DeepMind until recently stepping aside to focus on the drug venture; he now serves as DeepMind's chairman [3]. Hassabis and then-director of DeepMind John Jumper won the Nobel Prize in Chemistry for AlphaFold, the protein-structure prediction system [3].

AlphaFold predicts the 3D structure of proteins [3]. Isomorphic's bet is that similar approaches, extended across chemical space, disease pathways and drug modalities, can systematically produce clinical candidates — a proposition the industry has yet to prove at scale.

What remains unknown

  • The company's valuation and the ownership stake sold in this round.
  • How many internal candidates are in preclinical development, their targets, or when any might file for first-in-human studies.
  • Whether the "AI-first translational and clinical development infrastructure" means building internal clinical operations or partnering for them.
  • How IsoDDE's performance compares to other platforms on prospective benchmarks, as opposed to retrospective analyses.

The funding gives Isomorphic a runway to attempt a milestone that has yet to be convincingly demonstrated by an AI-first drug company: deliver multiple clinical candidates from its own engine and show that the success rate, speed or cost structure differs materially from traditional discovery. Until candidates enter human trials and generate safety and efficacy data, the $7.7 billion invested remains a bet on potential rather than proof.

Sources

  1. Isomorphic Labs announces $5 Billion Series C funding (prnewswire.com)
  2. Isomorphic Labs Raises $5 Billion, with a16z Joining (biopharmatrend.com)
  3. Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials | TechCrunch (techcrunch.com)
  4. Reimagining Drug Discovery Process with AI - Isomorphic Labs (isomorphiclabs.com)